The offer would constitute 10 per cent of the fully diluted post-issue paid-up capital of the company. Biocon will list the equity shares on The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd.
Biocon chairman and managing director Kiran Mazumdar-Shaw said in a press statement, We intend to utilise the proceeds of the public offering for Biocons expansion programme, which encompasses a large-scale facility and a state-of-the-art R&D laboratory.
DSP Merrill Lynch and Kotak Mahindra Capital Company are the book running lead managers while HSBC Securities & Capital Markets (India) is the Co-Book Running Lead Manager. Karvy Consultants Ltd is the registrar to the issue.